MedeliX
Start asking

Cyproheptadine

Prakten, Sipraktin, Vina Elixir · ATC code R06AX02

Also known as: Cyproheptadin, cyproheptadine alhavi 4

Key facts
Active substance
Cyproheptadine
Drug class
Histamine antagonist
ATC code
R06AX02
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-27

Key facts

Cyproheptadine is an antihistamine with anticholinergic properties. Per the US label it is used for allergic rhinitis, conjunctivitis, urticaria and other allergic reactions.

What it is used for

  • Perennial and seasonal allergic rhinitis; vasomotor rhinitis
  • Allergic conjunctivitis due to inhalant allergens and foods
  • Mild allergic skin manifestations of urticaria and angioedema; cold urticaria; dermatographism
  • Amelioration of allergic reactions to blood or plasma
  • Adjunct to epinephrine in anaphylaxis after the acute manifestations have been controlled

Dosing

  • Dosage is individualised; each tablet contains 4 mg
  • Children 2 to 6 years: usually 2 mg two or three times a day, not exceeding 12 mg a day
  • Children 7 to 14 years: usually 4 mg two or three times a day, not exceeding 16 mg a day
  • Adults: start with 4 mg three times a day; therapeutic range 4 to 20 mg a day, not exceeding 0.5 mg/kg/day

Contraindications

  • Newborn or premature infants; nursing mothers
  • Hypersensitivity to cyproheptadine or drugs of similar chemical structure
  • Monoamine oxidase inhibitor therapy
  • Angle-closure glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck or pyloroduodenal obstruction
  • Elderly, debilitated patients

Important warnings

  • Overdosage, particularly in infants and young children, may cause hallucinations, CNS depression, convulsions, respiratory and cardiac arrest, and death
  • May diminish mental alertness; in young children occasionally excitation
  • Caution with driving or operating machinery
  • Dizziness, sedation and hypotension more likely in elderly patients

Side effects

  • Sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion
  • Dry mouth, nausea, vomiting, constipation, increased appetite/weight gain
  • Urinary retention, blurred vision, tachycardia, hypotension
  • Also reported: haemolytic anaemia, agranulocytosis, hepatitis, hepatic failure, anaphylactic shock

Interactions

  • MAO inhibitors prolong and intensify anticholinergic effects
  • Additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers)

Pregnancy and breastfeeding

  • Use during pregnancy only if clearly needed
  • Contraindicated in nursing mothers

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Turkey

  • PraktenORBİS PHARMA İLAÇ VE KİMYA KOZMETİK MEDİKAL SAN. TİC. LTD. ŞTİ. · 1 register entry
  • SipraktinMENARİNİ SAĞLIK VE İLAÇ SAN. TİC. A.Ş. · 2 register entries
  • Vina ElixirHÜSNÜ ARSAN İLAÇLARI A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 1 more European countries
Portugal
Viternum

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. Cyproheptadine Hydrochloride (TRUPHARMA, LLC) – Prescribing Information, 2026-08-20. DailyMed (NLM), 2026-10-27. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c0b47c0-ecd2-450f-9dcb-c262db92866e
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC R06AX.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.